Clin2
NCT01174121Possibly a fitRecruiting

Immunotherapy made from your tumor-fighting immune cells

Metastatic Colorectal CancerMetastatic Pancreatic CancerMetastatic Ovarian CancerMetastatic Breast CarcinomaMetastatic Endocrine Tumors/ Neuroendocrine Tumors

Treatments studied

Part of Cancer, Digestive system, Hormones & metabolism, Kidney & urinary, Skin, Women’s health & pregnancy clinical trials.

This trial tests a treatment made from your own immune cells (called tumor-infiltrating lymphocytes, or TILs) for certain metastatic cancers. It’s designed for people whose cancer has not responded to standard treatments and who can safely provide a small tumor sample for cell-making.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 2
Enrollment
332 people
Ages
18 years to 72 years
Study type
Interventional

Who can take part

  • You have metastatic cancer in an allowed type (GI/upper or lower, liver/bile ducts, genitourinary, breast, ovarian/endometrial, or certain endocrine tumors like neuroendocrine).
  • Your cancer has at least one visible spot that can be removed safely so TILs can be made from the tumor tissue.
  • Your cancer has been treated with standard medicines already and is considered “refractory” (not responding or no longer responding), based on your cancer type.
  • You’re age 18 to 72, and you’re well enough to do daily activities (ECOG 0 or 1).
  • If you have up to 3 small, symptom-free brain metastases (under 1 cm), you may qualify if they’re stable after treatment—or they’ve been removed surgically.
  • Your blood and organ test results are adequate (for example, enough white blood cells, platelets, hemoglobin, and acceptable liver/kidney function), and you can complete consent.

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT07255664Recruiting· Phase 1/Phase 2
TIL therapy for advanced colorectal or prostate cancer

This trial tests a new type of immunotherapy that uses your own white blood cells (TILs) to fight advanced colorectal or prostate cancer. You will have surgery to remove a tumor, then your TIL cells are grown in a lab and given back to you along with other treatments to boost your immune system.

Frankfurt
NCT03412877Recruiting· Phase 2
Personalized immune-cell therapy for advanced metastatic cancers

This trial tests a personalized cell therapy made from your own immune cells, changed to recognize “neoantigens” on cancer cells. It’s designed for people with metastatic (advanced spread) solid cancers or certain other cancers who have tried standard treatments but cancer is still growing.

Bethesda, Maryland
NCT02621021Recruiting· Phase 2
Immune cell therapy for advanced melanoma

This trial tests a treatment that uses your own immune cells, called tumor-infiltrating lymphocytes (TILs), to fight melanoma. Some participants also get a drug called pembrolizumab. The goal is to see if this approach can shrink tumors.

Bethesda, Maryland
NCT02133196Recruiting· Phase 2
T-cell treatment for lung cancer that has spread

This Phase 2 study tests a T-cell–based immunotherapy for people with metastatic non-small cell lung cancer that has grown despite prior treatment. It may help your immune system recognize and fight your cancer using cells made from your tumor.

Bethesda, Maryland
NCT03658785Recruiting· Phase 1/Phase 2
Immunotherapy for advanced solid tumors using patient tumor cells

This trial tests an immunotherapy made from your own tumor-fighting immune cells (TIL). It may help people with advanced solid cancers that cannot be cured with surgery or radiation.

Wuhan, Hubei
NCT06530303Recruiting· Phase 1/Phase 2
Personalized immune cell therapy for colorectal cancer

This trial tests a treatment made from your own immune cells (called TILs) that are taken from your tumor, grown in a lab, and given back to you along with immunotherapy. It is for people with advanced colon or rectum cancer who have run out of standard options.

Beijing, Beijing Municipality

Hear when a new Metastatic Colorectal Cancer trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.